- Trials with a EudraCT protocol (4,361)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,361 result(s) found for: Physician.
Displaying page 1 of 219.
EudraCT Number: 2013-000277-72 | Sponsor Protocol Number: ARRAY-162-311 | Start Date*: 2013-09-18 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or... | |||||||||||||
Medical condition: Recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) CZ (Completed) DE (Completed) IE (Prematurely Ended) FI (Completed) NO (Completed) NL (Completed) SE (Completed) PL (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002527-21 | Sponsor Protocol Number: AMYPAD-01 | Start Date*: 2018-05-23 |
Sponsor Name:University of Geneva | ||
Full Title: Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzh... | ||
Medical condition: Alzheimer's disease Mild Cognitive Impairment Subjective Cognitive Decline Plus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DE (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000313-33 | Sponsor Protocol Number: NL72651 | Start Date*: 2020-07-08 |
Sponsor Name:UMC Utrecht | ||
Full Title: ‘Bronchodilators for wheeze in young children presenting to primary care: a randomised, placebo-controlled, multicentre, parallel group trial’ | ||
Medical condition: Wheezing in infants and young children (6-24 months old) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) BE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001909-25 | Sponsor Protocol Number: | Start Date*: Information not available in EudraCT |
Sponsor Name: | ||
Full Title: Effekter av behandling med atomoxetine ved komorbid ADHD hos pasienter med Pervasive Developmental Disorders (Effects of treatment with atomoxetine in children with Pervasive Developmental Disorder... | ||
Medical condition: Open treatment with atomoxetine for 10 weeks: •Week 1: 0,5 mg/kg/day in 1 or 2 doses. •Week 2 – 6: 1,2 mg/kg/day i 1 or 2 doses. •Week 6 – 8: Significant improvements: Continue on 1,2 mg/kg/day in ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002601-19 | Sponsor Protocol Number: OND-URG | Start Date*: 2019-09-16 |
Sponsor Name:Basque Health Service | ||
Full Title: Effectiviness and safety of the administration of ondansetron versus placebo for the treatment of vomit in children with mild and moderate dehydration: randomized clinical trial | ||
Medical condition: Vomiting | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002118-39 | Sponsor Protocol Number: 0000-027-00 | Start Date*: 2005-07-12 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: RECAP-DM (Real-life Effectiveness and Care Patterns of Diabetes Management) | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000904-14 | Sponsor Protocol Number: M19-164 | Start Date*: 2019-11-26 | |||||||||||
Sponsor Name:AbbVie | |||||||||||||
Full Title: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to ... | |||||||||||||
Medical condition: Plaque Psoriasis / Psoriasis Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000311-34 | Sponsor Protocol Number: P07642 | Start Date*: 2011-11-29 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects with Active Axial Spondyloarthritis (Phase 3b, Protocol No. P0... | |||||||||||||
Medical condition: Active Axial Spondyloarthritis (SpA) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FI (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000371-39 | Sponsor Protocol Number: MK-4280A-008 | Start Date*: 2022-08-31 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractor... | |||||||||||||
Medical condition: PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004355-37 | Sponsor Protocol Number: B5301001 | Start Date*: 2013-06-04 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06473871 IN REDUCING HYPERTROPHIC SKIN SCARRING | ||
Medical condition: Hypertrophic skin scarring | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) HU (Completed) ES (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006878-23 | Sponsor Protocol Number: APHP200023 | Start Date*: 2022-08-12 |
Sponsor Name:Assistance Publique Hopitaux Paris - APHP | ||
Full Title: Efficacy of Ruxolitinib as first line treatment in primary haemophagocytic lymphohistiocytosis (HLH) in children: a Phase 2, multicentre, non-comparative study R-HLH | ||
Medical condition: • Patient with Haemophagocytic lymphohistiocytosis (HLH) or lymphohistiocytic syndrome | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004368-31 | Sponsor Protocol Number: I1F-MC-RHBC | Start Date*: 2012-09-13 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A 12-Week Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psorias... | |||||||||||||
Medical condition: Moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003953-34 | Sponsor Protocol Number: 101-001 | Start Date*: 2009-12-14 |
Sponsor Name:D2 Derma Europe Ltd. | ||
Full Title: A randomized, placebo-controlled, active comparator, observer-blinded multicentre phase II trial to evaluate the efficacy and safety of D2D001 in the treatment of HSV type 1 infection in the region... | ||
Medical condition: Herpes simplex virus type 1 infection in the region of the mouth and the openings of the nose | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001352-13 | Sponsor Protocol Number: (ISA05-25) | Start Date*: 2006-09-27 |
Sponsor Name:Isotechnika Inc | ||
Full Title: A PHASE III, RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO AND CYCLOSPORINE CONTROLLED STUDY OF ISA247 IN PLAQUE PSORIASIS PATIENTS (ISA05-25) | ||
Medical condition: Patient has stable, moderate to severe, plaque psoriasis over the previous 6 months; i.e., psoriasis must not be spontaneously improving or worsening in the 4 weeks prior to the screening visit. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004776-20 | Sponsor Protocol Number: BAP00626 | Start Date*: 2006-03-27 |
Sponsor Name:Basilea Pharmaceutica Ltd | ||
Full Title: Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis | ||
Medical condition: Severe Chronic Hand Dermatitis (CHaD) Refractory to Topical Therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005197-78 | Sponsor Protocol Number: 1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Queen's Medical Centre, Nottingham, University Hospital NHS Trust, | |||||||||||||
Full Title: A multi-centre, randomised, parallel group, cross-over study comparing the efficacy and safety of double versus multiple injections of Botulinum Toxin type-A (Dysport®), into the gastrocnemius musc... | |||||||||||||
Medical condition: Spasticity of the Gastrocnemius Muscle due to Cerebral Palsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003722-24 | Sponsor Protocol Number: MOB015B-II | Start Date*: 2012-10-17 |
Sponsor Name:Moberg Derma AB | ||
Full Title: An open, single-centre pilot study of efficacy and safety of topical MOB015B in the treatment of distal subungual onychomycosis (DSO) | ||
Medical condition: Distal subungual onychomycosis (DSO) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002159-89 | Sponsor Protocol Number: NLD-PEG-14-10784 | Start Date*: 2015-11-05 |
Sponsor Name:Biogen MA | ||
Full Title: Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated with Sub-cutaneous Administration of Peginterferon beta-1a | ||
Medical condition: Erythema at injection site after Plegridy injection for the treatment of Multiple Sclerose. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002112-26 | Sponsor Protocol Number: 139B7 | Start Date*: 2007-05-21 |
Sponsor Name:YORK Pharma GmbH | ||
Full Title: Open, single-arm phase-III study to investigate the percutaneous absorption of abafungin after topical dermal application of Abafungin cream 1.0 % (YORK Pharma GmbH) in 20 patients with tinea pedis... | ||
Medical condition: Tinea pedis interdigital | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004748-37 | Sponsor Protocol Number: MK-0476-367 | Start Date*: 2015-04-03 |
Sponsor Name:MSD Korea LTD. | ||
Full Title: Korean Study of “Real-world” Montelukast Use in Mild Asthmatic Children with Concomitant Allergic Rhinitis | ||
Medical condition: mild asthma and allergic rhinitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
